AABB24: Meghan Delaney, DO, MPH, Inaugurated as New President of AABB

Meghan Delaney, DO, MPH, was officially installed as the new AABB president on Tuesday, following the conclusion of the 2024 AABB Annual Meeting in Houston.

Delaney is the chief of the division of pathology and laboratory medicine, and the director of transfusion medicine, at Children’s National Hospital. She is also a professor of pathology and pediatrics at the George Washington University in Washington, DC. Delaney previously worked at Bloodworks NW.

Delaney is a longtime and active AABB member, who has served as a member of the Board of Directors for several years prior to becoming president. She has been active in multiple AABB committees, including the AABB Distance Learning Committee, the Accreditation Program Committee, the Molecular Testing Accreditation Committee, the Nominating Committee, the Transfusion Medicine Subsection and its Pediatric Subcommittee, and the Global Transfusion Forum.

In her inaugural address, Delaney stressed that AABB has been her “professional home” throughout her career and she was honored to now begin her year of service as president of the Association. “I first joined AABB as a transfusion medicine resident and have attended every AABB Annual Meeting since 2006,” she said. “AABB has provided me with immense benefits throughout my career – from the knowledge I have gained through the education programs and my participation in the Annual Meetings, to my membership on committees, and to the strong connections I have made with countless fellow AABB members.”

Delaney acknowledged the legacy of our Association and vowed to continue to strengthen the AABB community. “I am proud to be part of an Association that continues to drive advancements in quality and safety throughout the world – and has done so for more than 75 years,” she said. “I take seriously the responsibility to build on this Association’s history and legacy as I begin my term as president.”

Looking to the year ahead, Delaney stressed AABB’s role and responsibility in promoting safety, quality and public health throughout the world. “I believe we can continue to expand AABB’s commitment to our members, while further cultivating our global role,” she said. “Doing so further fulfills our mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide. We know that many blood and biotherapies professionals are seeking ways to advance safety and quality for donors and patients throughout the world. AABB is well positioned to assist in these efforts and to use this opportunity to help advance public health and improve lives globally.”

AABB members can learn more about Delaney and the 2024-25 Board of Directors online.